Friday, 21 Feb 2020

You are here

Variations in First Biologic Use in Rheumatoid Arthritis

A Canadian analysis shows that rheumatoid arthritis (RA) patients are more likely to receive biologic DMARDs earlier if they are younger, female, and living in urban areas closer to prescribers. However usage patterns were not uniform across patients and prescribers given similar disease characteristics in a population with identical health insurance coverage. 

Physician preference was strongly associated with differences in time from first conventional synthetic DMARD to first biologic DMARD.

Factors governing a physicans choice of first biologic therapy in RA are numerous but vague as there are many to consider - physician experience, patient preference, their payer limitations, costs, toxicities and individual clinical scenarios.  Despite variations in physician use, there is little evidence that one biologic is superior to another when starting biologic therapy in RA.

All RA patients in Canada have identical comprehensive health insurance coverage, making it an ideal setting to study this issue.  This cohort RA study used administrative data and patient-level data on 17672 older RA patients from Ontario, Canada seen between 2002 and 2015, and who had received at least 1 csDMARD. 

Those more likely to have delays in receiving a biologic were the elderly , males, and distance from the nearest rheumatologist (HR per 10-km increase, 0.99; 95% CI, 0.98-0.99; P < .001).

Biologics were prescribed primarily by rheumatologists (71%) and less so by primary care physicians (12%).  A total of 214 unique prescribers had written 10 or more biologic prescriptions during the study period. Older p

Since the introduction of biologic therapies rheumatologists’ preferences (ie, yearly prescription rates) increased over time, from 1.7% in 2001 to 4.9% in 2015. Older physicians and those in rural areas were less likely to prescribe a first time biologic.

After adjusting for calendar year, patient, prescriber, and region, there was considerable variation between prescribers in of prescribing a first biologic DMARD (65% variance).  The reasons for this variation were not available from these data sets. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Tofacitinib Effective in Refractory Still's Disease

Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in patients with refractory adult-onset Still’s disease (AOSD), further adding to a growing list of potential use of JAK inhibition in managing inflammatory, and now autoinflammatory, disease.

QD Clinic - Hepatitis B and Biologics

QD Clinic - Lessons from the clinic Active HBV infection (HGsAg+) on anti-viral therapy but needs a biologic - what should you use?

Biosimilars for Rheum Disease: Failure to Launch

The availability of biologic biosimilars has thus far had negligible impact on prescribing practices in the United States, in stark contrast to what has been observed in some European countries, researchers reported.

Best of 2019 - Is Methotrexate Necessary with Tofacitinib?

Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant worsening of disease activity, a researcher reported at EULAR 2019 in Madrid.

Best of 2019 - Ups and Downs with Abatacept

Two recent studies have examined the effect of starting abatacept upon the risk of serious hospitalized infections or cancer, showing divergent results from claims data analyses.